These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

468 related items for PubMed ID: 27383190

  • 1. The usefulness of fluorine-18 fluorodeoxyglucose PET in the detection of recurrence in patients with differentiated thyroid cancer with elevated thyroglobulin and negative radioiodine whole-body scan.
    Stangierski A, Kaznowski J, Wolinski K, Jodlowska E, Michaliszyn P, Kubiak K, Czepczynski R, Ruchala M.
    Nucl Med Commun; 2016 Sep; 37(9):935-8. PubMed ID: 27383190
    [Abstract] [Full Text] [Related]

  • 2. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging 18F-FDG PET/CT.
    Okuyucu K, Ince S, Alagoz E, Emer O, San H, Balkan E, Ayan A, Meric C, Haymana C, Acıkel C, Gunalp B, Karacalioglu AO, Arslan N.
    Hell J Nucl Med; 2016 Sep; 19(3):208-217. PubMed ID: 27824959
    [Abstract] [Full Text] [Related]

  • 3. Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results.
    Ozkan E, Aras G, Kucuk NO.
    Clin Nucl Med; 2013 May; 38(5):326-31. PubMed ID: 23486319
    [Abstract] [Full Text] [Related]

  • 4. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan.
    Trybek T, Kowalska A, Lesiak J, Młynarczyk J.
    Nucl Med Rev Cent East Eur; 2014 May; 17(2):87-93. PubMed ID: 25088108
    [Abstract] [Full Text] [Related]

  • 5. Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level.
    Na SJ, Yoo IeR, O JH, Lin C, Lin Q, Kim SH, Chung SK.
    Ann Nucl Med; 2012 Jan; 26(1):26-34. PubMed ID: 21971605
    [Abstract] [Full Text] [Related]

  • 6. Optimal threshold of stimulated serum thyroglobulin level for 18F-FDG PET/CT imaging in patients with thyroid cancer.
    Chai H, Zhang H, Yu YL, Gao YC.
    J Huazhong Univ Sci Technolog Med Sci; 2017 Jun; 37(3):429-432. PubMed ID: 28585147
    [Abstract] [Full Text] [Related]

  • 7. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data.
    Vural GU, Akkas BE, Ercakmak N, Basu S, Alavi A.
    Clin Nucl Med; 2012 Oct; 37(10):953-9. PubMed ID: 22899202
    [Abstract] [Full Text] [Related]

  • 8. The role of FDG-PET/CT in differentiated thyroid cancer patients with negative iodine-131 whole-body scan and elevated anti-Tg level.
    Asa S, Aksoy SY, Vatankulu B, Aliyev A, Uslu L, Ozhan M, Sager S, Halac M, Sonmezoglu K.
    Ann Nucl Med; 2014 Dec; 28(10):970-9. PubMed ID: 25120245
    [Abstract] [Full Text] [Related]

  • 9. The role of FDG-PET in localization of recurrent lesions of differentiated thyroid cancer (DTC) in patients with asymptomatic hyperthyroglobulinemia in a real clinical practice.
    Kukulska A, Krajewska J, Kołosza Z, Paliczka-Cies Lik E, Puch Z, Gubała E, Król A, Kalemba M, Kropin Ska A, Jarząb B.
    Eur J Endocrinol; 2016 Nov; 175(5):379-85. PubMed ID: 27511823
    [Abstract] [Full Text] [Related]

  • 10. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P, Kuhn-Lansoy C, Edet-Sanson A, Hapdey S, Modzelewski R, Hitzel A, d'Anjou J, Basuyau JP.
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [Abstract] [Full Text] [Related]

  • 11. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
    Salvatore B, Paone G, Klain M, Storto G, Nicolai E, D'Amico D, Della Morte AM, Pace L, Salvatore M.
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
    [Abstract] [Full Text] [Related]

  • 12. 18F-FDG-PET/CT in Patients Affected by Differentiated Thyroid Carcinoma with Positive Thyroglobulin Level and Negative 131I Whole Body Scan. It's Value Confirmed by a Bicentric Experience.
    Bertagna F, Albano D, Bosio G, Piccardo A, Dib B, Giubbini R.
    Curr Radiopharm; 2016 Mar; 9(3):228-234. PubMed ID: 27210819
    [Abstract] [Full Text] [Related]

  • 13. Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels.
    Leboulleux S, El Bez I, Borget I, Elleuch M, Déandreis D, Al Ghuzlan A, Chougnet C, Bidault F, Mirghani H, Lumbroso J, Hartl D, Baudin E, Schlumberger M.
    Thyroid; 2012 Aug; 22(8):832-8. PubMed ID: 22853728
    [Abstract] [Full Text] [Related]

  • 14. Value of the negative PET-FDG in the middle term follow-up of differentiated thyroid cancer in patients with negative 131 I-Na scan and elevated thyroglobulin serum levels.
    Pachón-Garrudo VM, Cuenca-Cuenca JI, Ruiz-Franco-Baux J, Borrego-Dorado I, Tirado-Hospital JL, Navarro-González E, Vázquez-Albertino R.
    Rev Esp Med Nucl Imagen Mol; 2012 Aug; 31(6):315-21. PubMed ID: 23084014
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of the usefulness of positron emission tomography with [18F]fluorodeoxylglucose performed to detect non-radioiodine avid recurrence and/or metastasis of differentiated thyroid cancer - a preliminary study.
    Kolodziej M, Saracyn M, Lubas A, Brodowska-Kania D, Mazurek A, Dziuk M, Dymus J, Kaminski G.
    Nucl Med Rev Cent East Eur; 2021 Aug; 24(2):63-69. PubMed ID: 34382670
    [Abstract] [Full Text] [Related]

  • 16. 18F-FDG PET/CT and ultrasonogrpahy in differentiated thyroid carcinoma patients with elevated serum levels of antithyroglobulin antibody, negative Tg and whole body 131I scan.
    Liu J, Liu B, Yu Y, Chao F, Liu Y, Han X.
    Hell J Nucl Med; 2018 Aug; 21(1):24-27. PubMed ID: 29550843
    [Abstract] [Full Text] [Related]

  • 17. [Diagnostic accuracy of 18F-FDG PET in residual or recurrent differentiated thyroid carcinoma with high thyroglobulin and negative 131-I whole-body scan].
    Cabrera Martín MN, Pasamontes Pingarrón JA, Carreras Delgado JL, Lapeña Gutiérrez L, Delgado Bolton RC, Bittini Copano A, Pérez Castejón MJ, Fernández Pérez C.
    Rev Esp Med Nucl; 2007 Aug; 26(5):263-9. PubMed ID: 17910834
    [Abstract] [Full Text] [Related]

  • 18. The additive clinical value of 18F-FDG PET/CT in defining the recurrence of disease in patients with differentiated thyroid cancer who have isolated increased antithyroglobulin antibody levels.
    Ozkan E, Soydal C, Araz M, Aras G, Ibis E.
    Clin Nucl Med; 2012 Aug; 37(8):755-8. PubMed ID: 22785502
    [Abstract] [Full Text] [Related]

  • 19. Clinical and pathological factors related to 18F-FDG-PET positivity in the diagnosis of recurrence and/or metastasis in patients with differentiated thyroid cancer.
    Esteva D, Muros MA, Llamas-Elvira JM, Jiménez Alonso J, Villar JM, López de la Torre M, Muros T.
    Ann Surg Oncol; 2009 Jul; 16(7):2006-13. PubMed ID: 19415387
    [Abstract] [Full Text] [Related]

  • 20. Could [18]F-fluorodeoxyglucose PET/CT change the therapeutic management of stage IV thyroid cancer with positive (131)I whole body scan?
    Piccardo A, Foppiani L, Morbelli S, Bianchi P, Barbera F, Biscaldi E, Altrinetti V, Villavecchia G, Cabria M.
    Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):57-65. PubMed ID: 21285923
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.